CSL Limited CSLLY
35.02 USD +0.38 (+1.10%)
Nov 4, 2026, 1:47 PM EST
34.68 Day range 35.06
16.01 52-week range 35.64
- YTD
- +21.60%
- 1 year
- +22.62%
- Market cap
- 67.22B
- EPS (ttm)
- -1.34
- YTD return
- +21.60%
- 1-year return
- +22.62%
- Volume
- 1.19K
- Avg volume
- 91.13K
- Open
- 34.94
- Previous close
- 34.64
- Day's range
- 34.68 – 35.06
- 52-week range
- 16.01 – 35.64
2Y -11.83 (-25.23%)
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 10, 2026 | Dec 31, 2025 | — | 0.055 | — | — |
| Feb 10, 2025 | Dec 31, 2024 | — | 0.2594 | — | — |
News
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript 
CSL appoints Deborah Waterhouse as CEO & Managing Director 
Australia's CSL appoints Deborah Waterhouse as CEO 
HRMY vs. CSLLY: Which Stock Is the Better Value Option? 
CSL y Alentis desarrollarán y comercializarán lixudebart para enfermedades renales y hepáticas raras 
CSL strikes US$1.6 billion licensing deal for rare disease drug 
CSL strikes rare disease drug deal worth up to $1.6 billion with Swiss firm Alentis 
CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases 
Australia's CSL taps Amazon's cloud unit to boost research pipeline 
Lancet Publication Marks Important Advance in Influenza Prevention for Older Adults
Your note
Sign in to keep a note on CSLLY — it syncs with the Stock Master app.